Actions of immunosuppressor drugs on the development of an experimental ovarian tumor

Experimental Biology and Medicine

Volumn 227, Issue 8, 2002, Pages 658-664

  Sorianello, E ^a   Schillaci, R ^a   Chamson Reig, A ^a   Lux Lantos, V ^a   Libertun, C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cyclosporin A; Dexamethasone; Immunosuppression; Luteoma

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ESTRADIOL; FOLLITROPIN; IMMUNOSUPPRESSIVE AGENT; LUTEINIZING HORMONE; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RISK; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LUTEOMA; MOUSE; NONHUMAN;

ANIMALS; BODY WEIGHT; CYCLOSPORINE; DEXAMETHASONE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LUTEINIZING HORMONE; LUTEOMA; NEOPLASM TRANSPLANTATION; ORGAN SIZE; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; THYMUS GLAND; TRANSPLANTATION, HETEROTOPIC;

ANIMALIA; CASTOR;

EID: 0036733357     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Beverley P. Immunology of cancer. In: Franks LM, Teich NM, Eds. Introduction to the Cellular and Molecular Biology of Cancer. New York: Oxford University Press. pp311-329, 1997.
2. Sheil AGR. Development of malignancy following renal transplantation in Australia and New Zealand. Transplantation Proc 24:1275-1279, 1992.
3. Biskind M, Biskind G. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc ExpBiol Med 55:176-179, 1944.
4. Lux VAR. Tesone M, Larrea GA, Libertun C. High correlation between prolactinemia, 125-I hLH binding and progesterone secretion by an experimental luteoma. Life Sci 35:2345-2352, 1984.
5. Lux-Lantos VAR, Thyssen SM, Chamson-Reig A, Libertun C. Effect of a gonadotropin releasing hormone analog on an experimental ovarian tumor: direct and indirect actions. Life Sci 57:291-300, 1995.
6. Chamson-Reig A, Lux-Lantos VAR, Tesone M, Libertun C. GnRH receptors and GnRH endocrine effects on luteoma cells. Endocrine 6:165-171, 1997.
7. Chamson-Reig A, Bianchi MS, Rey-Roldán EB, Sorianello E, Libertun C, Lux-Lantos VA. Development of an experimental ovarian tumor over a year in the rat. Life Sci 65:1275-1285, 1999.
8. Hockl P, Sorianello E, Chamson-Reig A, Campo S, Groome N, Libertun C, Lux-Lantos V. Inhibins and FSH in the Early Development of an Experimental Ovarian Tumor. International workshop on inhibins, activins, follistatins. Monash Medical Center, Melbourne, Australia. Abstract book p 60. 2000.
9. Chamson-Reig A, Pignataro OP. Libertun C, Lux-Lantos V. Alterations in intracellular messengers mobilized by gonadotropin-releasing hormone in an experimental ovarian tumor. Endocrinology 148:3573-3580, 1999.
10. Clark RG, Holder AT. Ovarian-splenic autotransplantation: evidence that oestrogen does not inhibit hepatic somatomedin generation. J Endocrinol 103:43-47, 1984.
11. Vom Saal FS, Finch CE. Reproductive senescence: phenomena and mechanisms in mammals and selected vertebrates. In: Knobil E, Neill JD, Eds. The Physiology of Reproduction. New York: Raven Press, pp2351-2413, 1986.
12. Waterhouse J. Cancer Incidence in Five Continents. Lyons, France: IARC Scientific Publications, p15, 1976.
13. Rao RB, Slotman B. Endocrine factors in common epithelial ovarian cancer. Endocrine Rev 12:14-26, 1991.
14. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R. Ovarian stimulation and granulosa-cell tumour. Lancet 341:986-988, 1993.
15. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol 12:177-208, 1980.
16. MacLeod AF, Wleeler MJ, Gordon C, Lowy C, Sonksen PH, Conaglen JV. Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome. J Endocrinol 125:317-325, 1989.
17. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. Antigen localisation regulates immune response in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156:209, 1997.
18. Sigal NH, Dumont FJ. Cyclosporin A. FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519-560, 1992.
19. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 14:190-204, 2000.
20. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 84:304-315, 1976.
21. De Bosscher K, Shmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of nuclear factorκB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci U S A 94:13504-13509, 1997.
22. Rondinone CM, Schillaci R, Castillo MB, Roldán A. Inhibitory Effect of 11-hydroxypregna-1,4-diene-3,20-dione (A HOP) on lymphocyte proliferation. Clin Expt Immun 86:311-314, 1991.
23. Ashwell JD, Lu FWM, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 18:309-345, 2000.
24. Rondinone CM, Schillaci R, Lantos CP, Roldán A. Appearance and persistence of 11-hydroxypregna-1,4-diene-3,20-dione (ΔHOP) effect 'in vivo'. Acta Physiol Pharmacol Latinoamer 39:181, 1989.
25. Murphy P. Alexander P, Senior PV, Fleming J, Kirkham N, Taylor I. Mechanisms of organ selective tumour growth by bloodborne cancer cells. Br J Cancer 57:19-31, 1988.
26. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534, 1999.
27. DeSombre ER, Arbogast LY. Effect of the antiestrogen CI628 on the growth of rat mammary tumors. Cancer Res 34:1971-1974, 1974.
28. Sokal RR, Rohlf FJ. Biometry. New York: W.H. Freeman and Co., 1995.
29. Lison L. Datos enumerativos. Comparación de proporciones. Estadística aplicada a la biología experimental. Buenos Aires: Editorial Universitaria de Buenos Aires, pp307-327, 1976.
30. Sorianello E, Fritz S, Beyer C, Hales D, Mayerhofer A, Libertun C, Lux-Lantos V. Development of an experimental ovarian tumor: immunocytochemical analysis. Eur J Endocrinol, In Press.
31. Coirini H, Flores D, Vega MC, Gonzalez Deniselle MC, De Nicola AF. Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues: in vivo and in vitro studies. J Steroid Biochem Mol Biol 49:43-49, 1994.
32. Whiting PH, Simpson JG, Davidson RJL, Thomson AW. Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br J Exp Pathol 64:437-444, 1983.
33. Damoiseaux JGMC, Beijleveld LJJ, van Breda Vriesman PJC. Clin Immunol Immunopathol 82:197-202, 1997.
34. 3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol 61:133-138, 1989.
35. Sabharwal P, Varma S. Growth hormone synthesized and secreted by human thymocytes acts via insulin-like growth factor I as an autocrine and paracrine growth factor. J Clin Endocrinol Metab 81:2663-2669, 1996.
36. Beschorner WE, Divic J, Pulido H, Yao X, Kenworthy P, Bruce G. Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor I. Transplantation 52:879-884, 1991.
37. Esquifino Al, Moreno ML, Agrasal C, Villanúa MA. Effects of cyclosporine on ovarian function in sham-operated and pituitary-grafted young female rats. Proc Soc Exp Biol Med 208:397-403, 1995.
38. Pellegrini I, Lebrun J-J, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 6:1023-1031, 1992.
39. Russell DH, Matrisian L, Kibler R, Larson DF, Poulos B, Magun BE. Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Biochem Biophys Res Commun 121:899-906, 1984.
40. Woody MA, Welniak LA, Sun R, Tian ZG, Henry M, Richards S, Raziuddin A, Longo DL, Murphy WJ. Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Exp Hematol 27:811-816, 1999.
41. Van Nierkerk CC, Ramaekers FC, Hanselaar AG, Alderweireldt J, Poels LG. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 142:157-177, 1993.
42. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-1064, 2001.